There is currently no generic Brisdelle (paroxetine mesylate capsules) in the United States. Unexpired patents and exclusivity rights currently prevent any generic versions of the medication from being made until at least June 2017. However, certain circumstances could come up that may affect when a generic version is introduced, such as lawsuits or other patents for new uses.
Brisdelle™ (paroxetine mesylate capsules) is a prescription medication used to treat moderate-to-severe hot flashes that are caused by menopause. It belongs to a group of medicines known as selective serotonin reuptake inhibitors (SSRIs).
Brisdelle is made by Noven Therapeutics, LLC. It is protected from generic competition by patents and exclusivity rights that have not yet expired.
The first patent for Brisdelle is set to expire in June 2017. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to extend or delay this exclusivity period, including such things as lawsuits or other patents for new Brisdelle uses. Once Brisdelle goes off-patent, there may be several companies that manufacture a generic Brisdelle drug.
No -- paroxetine is the active ingredient in Brisdelle, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version of a medicine, the original medicine must have gone off-patent, and another company besides the original manufacturer must make the product.